Niagen Bioscience (NASDAQ:NAGE – Get Free Report) is one of 55 public companies in the “Personal Care Products” industry, but how does it compare to its peers? We will compare Niagen Bioscience to similar companies based on the strength of its institutional ownership, profitability, valuation, dividends, analyst recommendations, earnings and risk.
Valuation & Earnings
This table compares Niagen Bioscience and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | $17.38 million | 15.58 |
| Niagen Bioscience Competitors | $7.95 billion | $1.10 billion | 9.78 |
Niagen Bioscience’s peers have higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
Profitability
This table compares Niagen Bioscience and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 8.37% | 10.18% | 7.57% |
| Niagen Bioscience Competitors | -3.85% | -62.05% | 0.35% |
Analyst Recommendations
This is a summary of current ratings for Niagen Bioscience and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 4 | 1 | 3.00 |
| Niagen Bioscience Competitors | 908 | 2952 | 3667 | 229 | 2.41 |
Niagen Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 354.55%. As a group, “Personal Care Products” companies have a potential upside of 4.51%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than its peers.
Risk and Volatility
Niagen Bioscience has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Niagen Bioscience’s peers have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.
Summary
Niagen Bioscience beats its peers on 9 of the 13 factors compared.
Niagen Bioscience Company Profile
Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
